Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US9758509B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758509-B2 |
| Application number | US-201715451210-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2017 |
| Priority date | Jan 24, 2006 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula I, II, or III: or a pharmaceutically acceptable salt thereof, wherein:
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antineoplastic agents · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9758509B2 cover?
- The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D405/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).